SCHEMBL6825330

SCHEMBL6825330

CCOc1ccc2c(c1)CCC(Cc1c[nH]cn1)C2=O

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP24A1 Q07973 6/20 0.51
CYP27A1 Q02318 3/20 0.51
CYP19A1 P11511 3/20 0.51
CYP26A1 O43174 6/20 0.48
THRA P10827 2/20 0.48
THRB P10828 2/20 0.48
PPARD Q03181 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6825559 0.91 THRA (0.54) CYP24A1CYP27A1CYP19A1CYP26A1THRA
SCHEMBL6825419 0.91 CYP19A1 (0.51) CYP24A1CYP27A1CYP19A1CYP26A1THRA
SCHEMBL6825886 0.88 CYP19A1 (0.48) CYP24A1CYP27A1CYP19A1CYP26A1THRA
SCHEMBL6923943 0.81 CYP19A1 (0.64) CYP24A1CYP27A1CYP19A1CYP26A1
SCHEMBL337671 0.78 CYP19A1 (0.58) CYP19A1CYP26A1
SCHEMBL6827897 0.77 CYP19A1 (0.53) CYP24A1CYP27A1CYP19A1HTT
SCHEMBL7800750 0.77 CYP19A1 (0.44) CYP24A1CYP27A1CYP19A1CYP26A1
SCHEMBL7797555 0.75 CYP19A1 (0.48) CYP19A1CYP26A1
SCHEMBL8199809 0.73 HRH3 (0.53) CYP24A1CYP27A1THRATHRB
SCHEMBL7797575 0.73 CYP19A1 (0.48) CYP19A1CYP26A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028110-B1 NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME DAIICHI SEIYAKU CO (JP) 2004-04-14 EP disclosed
US-6559157-B2 Excellent 17 alpha - hydroxylase/C17-20-lyase and aromatase inhibiting activity, thromboxan A2 synthesis inhibiting activity, useful as preventive and/or therapeutic agents for various male and female sex hormone dependent diseases DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-05-06 US disclosed
US-20020032211-A1 Novel dihydronaphthalene compounds and processes of producing the same DAIICHI PHARMACEUTICALS CO., LTD. (JP) 2002-03-14 US disclosed
EP-1028110-A1 NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME Yukijirushi Nyugyo Kabushiki Kaisha (JP) 2000-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032211-A1 Novel dihydronaphthalene compounds and processes of producing the same CYP19A1, HSD17B11, CYP17A1 CYP24A1 180/4885CYP27A1 83/4885CYP19A1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.